Extracorporeal perfusion for the treatment of acute liver failure.

OBJECTIVE AND SUMMARY BACKGROUND DATA Because of the shortage of available donor organs, death rates from liver failure remain high. Therefore, several temporary liver-assisting therapies have been developed. This article reviews various approaches to temporary liver support as well as immunologic and metabolic developments toward a solution for this problem. METHODS A literature review was performed using Medline and additional library searches to obtain further references. Only articles with a well-defined aim of study and methodology and a clear description of the outcome of the experiments were included. CONCLUSIONS Renewed interest has developed in old and new methods for an extracorporeal approach to the treatment of acute liver failure. Although temporary clinical improvement has been established, further research is needed to achieve a successful long-term clinical outcome. New developments in the field of genetic modification and tissue engineering await clinical application in the near future.

[1]  M. Lepore,et al.  Plasmapheresis with Plasma Exchange in Hepatic Coma. , 1969 .

[2]  S. Nyberg,et al.  Immunoprotection of xenocytes in a hollow fiber bioartificial liver. , 1992, ASAIO journal.

[3]  Roger Williams,et al.  TREATMENT OF FULMINANT HEPATIC FAILURE BY POLYACRYLONITRILE-MEMBRANE HÆMODIALYSIS , 1977, The Lancet.

[4]  B. Lapin,et al.  Porcine endogenous retrovirus (PERV) was not transmitted from transplanted porcine endothelial cells to baboons in vivo , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[5]  N. Sussman,et al.  Reversal of fulminant hepatic failure using an extracorporeal liver assist device , 1992, Hepatology.

[6]  S. Schenker,et al.  ACUTE HEPATIC NECROSIS WITH STUPOR OR COMA An Analysis of Thiety‐One Patients , 1969, Medicine.

[7]  B. Loveland,et al.  Gal alpha(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. , 1994, Transplantation.

[8]  N Ohshima,et al.  Performance of a new hybrid artificial liver support system using hepatocytes entrapped within a hydrogel. , 1989, ASAIO transactions.

[9]  M. Matsushita,et al.  Development of a bioartificial liver with sandwiched-cultured hepatocytes between two collagen gel layers. , 2008, Artificial organs.

[10]  E. Condom,et al.  Functional and pathologic outcome after complement inactivation in a pig kidney-human blood xenoperfusion model. , 1997, Transplantation proceedings.

[11]  M. Rikimaru,et al.  Hybrid bioartificial liver in hepatic failure: preliminary clinical report. , 1987, Surgery.

[12]  Y. Yajima,et al.  Continuous removal of middle molecules by hemofiltration in patients with acute liver failure , 1990, Critical care medicine.

[13]  L. Vīksna,et al.  Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. , 1989, Resuscitation.

[14]  T. Komai,et al.  A hybrid bioartificial liver composed of multiplated hepatocyte monolayers. , 1988, ASAIO transactions.

[15]  H. Keen,et al.  Diurnal Variation of Oral Glucose Tolerance: a Possible Pointer to the Evolution of Diabetes Mellitus , 1969, British medical journal.

[16]  R. Tompkins,et al.  Expression of Long-Term Liver-Specific Function by Adult Rat Hepatocytes Cultured on Microcarriers , 1997 .

[17]  S. Saunders,et al.  Treatment of hepatic coma by exchange blood transfusion. , 1966, The New England journal of medicine.

[18]  J. Kiley,et al.  Removal of Blood Ammonia by Hemodialysis.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[19]  F. Cerra,et al.  Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. , 1995, The Journal of surgical research.

[20]  T. Giorgio,et al.  Mass Transfer in a Hollow Fiber Device Used as a Bioartificial Liver , 1993, ASAIO journal.

[21]  D. Milliner,et al.  Postdilution hemofiltration in the management of acute hepatic failure: a pilot study. , 1988, Mayo Clinic proceedings.

[22]  S. Nyberg,et al.  Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. , 1993, ASAIO journal (1992).

[23]  A. Gimson,et al.  EARLIER CHARCOAL HAEMOPERFUSION IN FULMINANT HEPATIC FAILURE , 1982, The Lancet.

[24]  R. Tompkins,et al.  Hepatocyte function and extracellular matrix geometry: long‐term culture in a sandwich configuration , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  J. McKechnie,et al.  Exchange transfusion in hepatic coma. A review of 19 cases. , 1971, The American journal of gastroenterology.

[26]  P. Opolon,et al.  Long-term extra-corporeal assistance by continuous haemofiltration during fulminant hepatic failure. , 1979, Gastroenterologie clinique et biologique.

[27]  A. Redeker,et al.  Controlled trial of exchange-transfusion therapy in fulminant hepatitis. , 1973, Lancet.

[28]  A. Shnyra,et al.  Bioartificial liver using hepatocytes on biosilon microcarriers: treatment of chemically induced acute hepatic failure in rats. , 1991, Artificial organs.

[29]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[30]  P. Neuhaus,et al.  Improved xenogeneic extracorporeal liver perfusion. , 1994, Transplantation proceedings.

[31]  L. Rosenberg,et al.  Mechanisms of resistance to injury in pig livers perfused with blood from patients in liver failure. , 1997, Transplantation proceedings.

[32]  E. Laterre,et al.  DEANOL IN SPONTANEOUS AND INDUCED DYSKINESIAS , 1975, The Lancet.

[33]  G. Abouna,et al.  TREATMENT OF HEPATIC COMA BY EXTRACORPOREAL PIG-LIVER PERFUSION , 1969 .

[34]  I. Bersohn,et al.  The influence of diet on serumtriglycerides in South Africa white and Bantu prisoners. , 1961, Lancet.

[35]  J. White,et al.  Evaluation of a hepatocyte‐entrapment hollow fiber bioreactor: A potential bioartificial liver , 1993, Biotechnology and bioengineering.

[36]  D. Cramer,et al.  REMOVAL OF NATURAL HUMAN XENOANTIBODIES TO PIG VASCULAR ENDOTHELIUM BY PERFUSION OF BLOOD THROUGH PIG KIDNEYS AND LIVERS , 1993, Transplantation.

[37]  L. Flendrig,et al.  Immunological Consequences of the use of Xenogeneic Hepatocytes in a Bioartificial Liver for Acute Liver Failure , 1997, The International journal of artificial organs.

[38]  R. Tompkins,et al.  Enzymatic function of alginate immobilized rat hepatocytes , 1988, Biotechnology and bioengineering.

[39]  R. Busuttil,et al.  Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. , 1997, Transplantation proceedings.

[40]  W. Meyers,et al.  Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. , 1994, The New England journal of medicine.

[41]  S. Satoh,et al.  Extracorporeal xenoperfusion of the pig liver as a liver assist device: effects of prostaglandin E1 and soluble complement receptor type 1. , 1998, Transplantation Proceedings.

[42]  T. Giorgio,et al.  Development of a bioartificial liver: Properties and function of a hollow‐fiber module inoculated with liver cells , 1993, Hepatology.

[43]  E. Wilander,et al.  Letter: Diabetogenic nitrosamines? , 1974, Lancet.

[44]  Roger Williams,et al.  PROSTACYCLIN TO PREVENT PLATELET ACTIVATION DURING CHARCOAL HÆMOPERFUSION IN FULMINANT HEPATIC FAILURE , 1980, The Lancet.

[45]  J. Platt,et al.  The pathogenesis of hyperacute xenograft rejection. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  P. Opolon,et al.  Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. , 1978, Gut.

[47]  J. Griffiss,et al.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora , 1988, Infection and immunity.

[48]  S. Levenson,et al.  New Method of Hepatocyte Transplantation and Extracorporeal Liver Support , 1986, Annals of surgery.

[49]  R. I. Hansen,et al.  Pig liver perfusion in the treatment of acute hepatic failure. , 1971, Scandinavian journal of gastroenterology. Supplement.

[50]  L. Leinwand,et al.  Hepatocyte proliferation in vitro: its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[51]  B. Collins,et al.  THE HUMORAL IMMUNE RESPONSE IN HUMANS FOLLOWING CROSS‐PERFUSION OF PORCINE ORGANS , 1995, Transplantation.

[52]  E. Tiula,et al.  Plasmapheresis with albumin as main substitute in acute hepatic coma. , 1972, Scandinavian journal of gastroenterology.

[53]  A. Pascher,et al.  Application of immunoapheresis for delaying hyperacute rejection during isolated xenogeneic pig liver perfusion. , 1997, Transplantation.

[54]  E. H. Dunlop,et al.  Charcoal haemoperfusion in the treatment of fulminant hepatic failure. , 1974, Lancet.

[55]  A. Tink,et al.  EXCHANGE TRANSFUSION IN HEPATIC COMA: REPORT OF A CASE , 1958 .

[56]  William M. Lee,et al.  Acute Liver Failure , 1999, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.

[57]  M. Slavik,et al.  Phase I clinical trials. , 1977, National Cancer Institute monograph.

[58]  J. Platt,et al.  Characterization and affinity isolation of xenoreactive human natural antibodies. , 1994, Journal of immunology.

[59]  G. Abouna,et al.  Long-term hepatic support by intermittent multi-species liver perfusions. , 1970, Lancet.

[60]  P. J. Brock,et al.  Extracorporeal pig-liver perfusoon in treatment of hepatic coma due to fulminant hepatitis. , 1971, Lancet.

[61]  W. Meyers,et al.  MECHANISMS OF INJURY IN PORCINE LIVERS PERFUSED WITH BLOOD OF PATIENTS WITH FULMINANT HEPATIC FAILURE , 1994, Transplantation.

[62]  T. M. Chang.  Haemoperfusions over microencapsulated adsorbent in a patient with hepatic coma. , 1972, Lancet.

[63]  R. Marquet,et al.  IgG, but not IgM, mediates hyperacute rejection in hepatic xenografting , 1999, Xenotransplantation.

[64]  S. A. Wilson,et al.  Disorders of motility and muscle tone with special reference to the corpus striatum , 1925 .

[65]  A. Demetriou,et al.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.

[66]  R. Hughes,et al.  Clinical Experience with Charcoal and Resin Hemoperfusion , 1986, Seminars in liver disease.

[67]  R Williams,et al.  Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure , 1996, Hepatology.

[68]  M V Peshwa,et al.  Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. , 1994, Annals of surgery.

[69]  J. Vienken,et al.  Side Effects of Hybrid Liver Support Therapy: TNF-α Liberation in Pigs, Associated with Extracorporeal Bioreactors , 1993, The International journal of artificial organs.

[70]  B. Eiseman,et al.  Heterologous liver perfusion in treatment of hepatic failure. , 1965, Annals of surgery.

[71]  H. Gooszen,et al.  HUMAN COMPLEMENT ACTIVATION VIA THE ALTERNATIVE PATHWAY ON PORCINE ENDOTHELIUM INITIATED BY IgA ANTIBODIES , 1995, Transplantation.

[72]  H. Dudley,et al.  Heterologous liver perfusion in acute hepatic failure. , 1967, British medical journal.

[73]  Achilles A. Demetriou,et al.  Development of a Hybrid Bioartificial Liver , 1993, Annals of surgery.

[74]  J. D. Lewis,et al.  Exchange transfusion in hepatic coma: factors affecting results, with long-term follow-up data. , 1975, American Journal of Surgery.

[75]  A. Matas,et al.  Hepatocellular transplantation in acute liver failure. , 1977, Surgery.

[76]  P. J. McKenna,et al.  Plasmapheresis with plasma exchange in hepatic coma. II. Fulminant viral hepatitis as a systemic disease. , 1972, Archives of internal medicine.

[77]  M. Matsushita,et al.  A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. , 1991, ASAIO transactions.

[78]  Walker Wr.  Radiation and arthritis. , 1978 .

[79]  A. Gimson,et al.  Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. , 1988, Gastroenterology.

[80]  M. Matsushita,et al.  Function of culturing monolayer hepatocytes by collagen gel coating and coculture with nonparenchymal cells. , 2008, Artificial organs.

[81]  Welch Cs,et al.  The use of a donor liver in experimental animals with elevated blood ammonia. , 1958 .

[82]  D. Jefferson,et al.  Culturing hepatocytes and other differentiated cells , 1984, Hepatology.

[83]  N. Sussman,et al.  The Hepatix extracorporeal liver assist device: initial clinical experience. , 1994, Artificial organs.

[84]  J. Waldschmidt,et al.  Experience in the Treatment of Hepatic Coma by Extracorporeal Liver Perfusion , 1981 .

[85]  C. Welch,et al.  The use of a donor liver in experimental animals with elevated blood ammonia. , 1958, Surgery.

[86]  Yasuhiro Takeuchi,et al.  Infection of human cells by an endogenous retrovirus of pigs , 1997, Nature Medicine.